Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 3Lymphoid 1

Conditions

Polycythemia Vera 3Thrombocythemia, Essential 2Primary Myelofibrosis 2Myeloproliferative Disorders 1Hodgkin Disease 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Has results × givinostat × Clear all
NCT00792467 2021-05-11

Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma

Italfarmaco

Phase 1/2 Completed
24 enrolled 13 charts
Lymphoid

Hodgkin Disease

NCT00606307 2019-12-03

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

Italfarmaco

Phase 2 Completed
29 enrolled 8 charts
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT00928707 2019-10-31

PV

Italfarmaco

Phase 2 Completed
45 enrolled 10 charts
Myeloid

Polycythemia Vera

NCT01901432 2019-07-30

A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera

Italfarmaco

Phase 1/2 Completed
48 enrolled 28 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡